Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Auteur de référence en rhumatologie
21 articles scientifiques publiés — un praticien à la pointe de la recherche
Cabinet de groupe — continuité de soins
Plusieurs praticiens dans le même cabinet — un confrère peut prendre le relais en cas d'absence
Disponibilité géographique
3 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
118.8 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
19
19 articles ont été cités au moins 19fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
1 680
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
93
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
23
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
2026ArticleClinical Cancer Research
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
2025ArticleNature Communications
CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients
2023ArticleBreast Cancer
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
2023ArticleJournal of Clinical Oncology
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)
2022ArticleGynecologic Oncology
Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients
2021ArticleFrontiers in Pharmacology
Attentes des patientes suivies pour un cancer de l’ovaire concernant les traitements d’entretien : résultats de la cohorte française GINECO de l’enquête européenne NOGGO/ENGOT-ov22 (Expression IV) [= Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]
2018ArticleBulletin du Cancer
Predicting early death in older adults with cancer
2018ArticleEuropean Journal of Cancer
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
SELAS CENTRE AZUREEN DE CANCEROLOGIE
999 BOULEVARD DE LA MER, 83600 FREJUS
HP A. TZANCK MOUGINS SOPHIA ANTIPOLIS
122 AV DU DOCTEUR MAURICE DONAT BP 1250, 06254 MOUGINS CEDEX
SELAS CENTRE AZUREEN DE CANCEROLOGIE
CENTRE AZUREEN DE CANCEROLOGIE 1 PL DU DOCTEUR JEAN LUC BROQUERIE, 06250 MOUGINS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The Lancet. Oncology · 2021
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2007
Purpose Trastuzumab plus chemotherapy has become the standard of care for human epidermal growth factor receptor-2 (HER-2) –positive breast cancer. Trastuzumab-based preoperative systemic therapy (PST; neoadjuvant therapy) also appears promising, warranting further investigation. Patients and Methods Patients with HER-2-positive, stage II/III, noninflammatory, operable breast cancer requiring a mastectomy (but who wanted to conserve the breast) received trastuzumab 4 mg/kg (day 1), followed by 2 mg/kg weekly, plus docetaxel 75 mg/m2 every 3 weeks, and carboplatin (area under curve, 6) for six cycles before surgery. The primary end point was pathologic complete response (pCR) rate, determined from surgical specimens. Results Seventy patients were enrolled. Most patients had clinical T2/T3 tumors (100%) or clinical N1/2 nodes (53%). Sixty-seven patients (96%) completed six cycles of therapy, one patient withdrew due to progressive disease, and two patients withdrew for toxicity. A complete or partial objective clinical response occurred in 95% of patients (85% and 10%, respectively). Surgery was breast conservative in 45 (64%) of 70 patients. In an intent-to-treat analysis, tumor and nodal pCR were seen in 27 (39%) of 70 patients. Centralized retrospective analysis of HER-2 status demonstrated a 43% pCR rate in the 24 of 56 confirmed HER-2-overexpressing (3+) and/or fluorescence in situ hybridization–positive tumors. Treatment was generally well tolerated. Grade 3/4 neutropenia and febrile neutropenia were uncommon (2%). Two patients withdrew prematurely due to a transient, asymptomatic decrease in left ventricular ejection fraction. No symptomatic cardiac dysfunction occurred. Conclusion PST with trastuzumab plus docetaxel and carboplatin achieved promising efficacy, with a good pCR rate and favorable tolerability in stage II or III HER-2-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
PURPOSE Platinum-based doublets with concurrent and maintenance bevacizumab are standard therapy for ovarian cancer (OC) relapsing after a platinum-free interval (PFI) >6 months. Immunotherapy may be synergistic with bevacizumab and chemotherapy. PATIENTS AND METHODS ATALANTE/ENGOT-ov29 (ClinicalTrials.gov identifier: NCT02891824 ), a placebo-controlled double-blinded randomized phase III trial, enrolled patients with recurrent epithelial OC, one to two previous chemotherapy lines, and PFI >6 months. Eligible patients were randomly assigned 2:1 to atezolizumab (1,200 mg once every 3 weeks or equivalent) or placebo for up to 24 months, combined with bevacizumab and six cycles of chemotherapy doublet, stratified by PFI, PD-L1 status, and chemotherapy regimen. Coprimary end points were investigator-assessed progression-free survival (PFS) in the intention-to-treat (ITT) and PD-L1–positive populations (alpha .025 for each population). RESULTS Between September 2016 and October 2019, 614 patients were randomly assigned: 410 to atezolizumab and 204 to placebo. Only 38% had PD-L1–positive tumors. After 3 years' median follow-up, the PFS difference between atezolizumab and placebo did not reach statistical significance in the ITT (hazard ratio [HR], 0.83; 95% CI, 0.69 to 0.99; P = .041; median 13.5 v 11.3 months, respectively) or PD-L1–positive (HR, 0.86; 95% CI, 0.63 to 1.16; P = .30; median 15.2 v 13.1 months, respectively) populations. The immature overall survival (OS) HR was 0.81 (95% CI, 0.65 to 1.01; median 35.5 v 30.6 months with atezolizumab v placebo, respectively). Global health-related quality of life did not differ between treatment arms. Grade ≥3 adverse events (AEs) occurred in 88% of atezolizumab-treated and 87% of placebo-treated patients; grade ≥3 AEs typical of immunotherapy were more common with atezolizumab (13% v 8%, respectively). CONCLUSION ATALANTE/ENGOT-ov29 did not meet its coprimary PFS objectives in the ITT or PD-L1–positive populations. OS follow-up continues. Further research on biopsy samples is warranted to decipher the immunologic landscape of late-relapsing OC.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
JCO oncology practice · 2026 · Journal Article
Contu S, Hebert C, Ferrero JM, Creisson A, et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026 · Journal Article
Beinse G, Leroy K, Just PA, Jeanne C, et al.
Nature communications · 2025 · Journal Article
Joly F, Leary A, Ray-Coquard I, Asselain B, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · Clinical Trial, Phase III
Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, et al.
Breast cancer (Tokyo, Japan) · 2023 · Multicenter Study
Bailleux C, Arnaud A, Frenel JS, Chabaud S, et al.
Gynecologic oncology · 2022 · Clinical Trial, Phase II
Trédan O, Provansal M, Abdeddaim C, Lardy-Cleaud A, et al.
The Lancet. Oncology · 2021 · Clinical Trial, Phase III
Pignata S, Lorusso D, Joly F, Gallo C, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013 · Clinical Trial, Phase II
Weber B, Largillier R, Ray-Coquard I, Yazbek G, et al.
Breast cancer research and treatment · 2012 · Clinical Trial, Phase II
Lortholary A, Hardy-Bessard AC, Bachelot T, de Rauglaudre G, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2007 · Comparative Study
Julian-Reynier C, Genève J, Dalenc F, Genre D, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2007 · Clinical Trial, Phase II
Coudert BP, Largillier R, Arnould L, Chollet P, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · Journal Article
Beinse G, Taly V, Leary A, Baures A, et al.
BMC cancer · 2020 · Journal Article
Chamorey E, Francois E, Etienne MC, Ferrero JM, et al.
Bulletin du cancer · 2018 · Journal Article
Lorcet M, Lortholary A, Kurtz JE, Berton-Rigaud D, et al.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2006 · Journal Article
Courdi A, Ortholan C, Hannoun-Lévi JM, Ferrero JM, et al.
International journal of radiation oncology, biology, physics · 2005 · Journal Article
Ortholan C, Hannoun-Lévi JM, Ferrero JM, Largillier R, et al.
Critical reviews in oncology/hematology · 2011 · Journal Article
Magné N, Melis A, Chargari C, Castadot P, et al.
Frontiers in pharmacology · 2021 · Journal Article
Berton D, Floquet A, Lescaut W, Baron G, et al.
Cancer · 2009 · Journal Article
Largillier R, Savignoni A, Gligorov J, Chollet P, et al.
Medical science monitor : international medical journal of experimental and clinical research · 2004 · Clinical Trial
Chamorey E, Magne N, Foa C, Otto J, et al.
Cancer chemotherapy and pharmacology · 2002 · Clinical Trial
Ferrero JM, Chamorey E, Magné N, Leccia F, et al.